Peter Chambré, a biopharmaceutical industry veteran, has been appointed chairman of the board of directors of Immatics Biotechnologies GmbH of Tübingen, Germany. Mr Chambré was chief executive of Cambridge Antibody Technology from 2002 until its acquisition by AstraZeneca Plc in 2006. Prior to this he was chief operating officer at the Celera Genomics Group and before that, CEO of Bespak Plc, a drug delivery company. Since 2008 he has held a number of chair and non-executive director posts including that of non-executive director of BTG Plc.
Immatics announced the appointment on 12 November 2012.
Copyright 2012 Evernow Publishing Ltd